Trial Profile

A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Narmafotinib (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions
Sponsors Amplia Therapeutics

20 Jun 2025 Status changed from planning to not yet recruiting.
09 Apr 2025 According to Amplia Therapeutics media release, company has announced that trial initiation activities for the planned pancreatic cancer trial in the US have begun.
03 Mar 2025 According to Amplia Therapeutics media release, Following a Type D meeting with the United States Food and Drug Administration (FDA), the company has received feedback on proposed modifications to our US clinical trial protocol for narmafotinib.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com